♥ HF Guideline NavigatorESC 2026

7

7 Decompensated heart failure

Pages 42–52 · open in PDF

Recommendations in this section

  • Class ILevel CCareful evaluation before discharge is recommended in patients hospitalized for DHF to exclude persistent signs of congestion.
  • Class ILevel B2An intensive strategy of rapid initiation and uptitration of FMT before discharge and during frequent follow-up visits in the first 6 weeks following an HFH is recommended to reduce the risk of HF rehospitalization or death.
  • Class ILevel COxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia.
  • Class ILevel CIntubation is recommended in patients with DHF and persistent and progressive respiratory failure despite oxygen administration or non-invasive ventilation to correct hypoxaemia.
  • Class IIaLevel B2Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress and reduce the risk of endotracheal intubation.
  • Class ILevel AIntravenous loop diuretics are recommended for all patients with DHF admitted with fluid overload to improve symptoms.
  • Class IIaLevel B1The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.
  • Class IIbLevel B1Urinary Na⁺-guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.
  • Class ILevel B1In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion symptoms and reduce the risk of HFH.
  • Class IIbLevel CIntravenous vasodilators may be considered as initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve symptoms and reduce congestion.
  • Class IIbLevel CInotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion.
  • Class IIbLevel CVasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ perfusion.
  • Class IIILevel CRoutine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm.
  • Class ILevel CA multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type) based on patient and HF characteristics.
  • Class IIaLevel B1Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no risk of hypoxic brain injury in order to reduce the risk of death.
  • Class IIILevel B1Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of harm.
  • Class IIILevel B1IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.
  • Class IIaLevel CTemporary MCS should be considered in patients with mechanical complications related to MI as a bridge to definitive treatment.
  • Class IIaLevel CTemporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB, BTC, or BTT.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 42 · PDF

42 with AF, the percentage of effective biventricular pacing (without fusion or pseudofusion) is an important focus. Further details on CRT follow-up and optimization are outlined in an HFA position paper.435

6.2.5. Other cardiac implantable electronic devices

6.2.6. Other implantable devices It has been hypothesized that an interatrial shunt could improve HF symptoms and outcomes by decompressing the left atrium. In the RELIEVE-HF study, 508 patients with HF and predominantly NYHA class III symptoms and any LVEF were randomized to transcatheter shunt implantation vs a sham procedure.442 After 2 years, no difference emerged in the primary effectiveness outcome [hierarchical composite ranking of all-cause death, cardiac transplantation or LV assist device (LVAD) implantation, HFH, outpatient WHF events, and change in QoL]. Importantly, patients with reduced LVEF had fewer adverse CV events with shunt treatment, whereas patients with HFpEF had more CV events. In the REDUCE LAP-HF II study in patients with LVEF ≥40%, the atrial shunt device was no better than the sham procedure in terms of the hierarchical composite of CV death or nonfatal ischaemic stroke at 12 months, rate of total HF events up to 24 months, and change in QoL at 12 months.443

7. Decompensated heart failure 7.1. Definition and epidemiology Decompensated HF is defined as acute or gradual onset of symptoms and/or signs of HF, severe enough to require urgent medical attention and treatment initiation or intensification. DHF can lead to an unplanned hospital admission, an emergency department visit, or an unplanned ambulatory visit requiring treatment for HF. DHF may present as either worsening of preexisting HF or as the initial manifestation of the disease (de novo HF). In the setting of patients with pre-existing HF, WHF is characterized by a deterioration in the symptoms and/or signs of HF and represents an event in HF progression, whereas DHF is specifically characterized by the requirement for treatment modification.444 Decompensated HF is associated with a high risk of death: 3%–10% during HF admission; 20%–30% at 1 year, >50% after 5 years.445–450 Compared to DHF occurring in patients with preexisting HF, de novo DHF may be associated with higher inhospital death, but lower post-discharge death and rehospitalization rates.451–453 Following a hospitalization for DHF, 1-year rehospitalization rates range between 35% and 44%.447,448,453–455 In addition, up to 50% of patients with HF

require intensification of treatment in the emergency service or in outpatient settings.456–462

7.2. Diagnosis Decompensated HF requires prompt diagnosis to ensure early treatment.463 If DHF is suspected, assessment of signs and symptoms of congestion and hypoperfusion must be done at the first medical contact. Non-invasive blood pressure, respiratory rate, pulse oximetry monitoring, body temperature measurement, and ECG should be performed early.464 In haemodynamically unstable patients with suspected hypoperfusion, assessment of serum lactate levels should be performed promptly.465 The currently recommended, non-age-adjusted, natriuretic peptide ‘rule-out’ thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL.157,466–469 However, if clinical suspicion of HF remains despite values below ‘rule-out’ thresholds, specialist assessment and echocardiogram should be sought. Age-related thresholds for NT-proBNP, above which DHF is considered ‘likely’, are given in the footnote of Figure 11. In the older population, using the age-related NT-proBNP threshold may aid appropriate triage and help reduce unnecessary exams. NT-pro-BNP >5000 pg/mL indicates very high risk, and admission is generally recommended. For other laboratory tests and investigations for patients with suspected DHF, see Supplementary data online, Table S11. Initial investigations are carried out to diagnose DHF and rapidly detect any possible triggers. Transthoracic echocardiography should be performed in patients with high levels of NT-proBNP and in those for whom there is a high clinical suspicion of DHF. Where trained personnel are available, lung ultrasound identifies patients with pulmonary congestion and has utility in serial assessments.470–473

7.3. Clinical presentation Congestion and hypoperfusion are two major clinical manifestations of DHF.447,453 Congestion may stem from fluid overload, fluid redistribution, increased vascular permeability, and increased intracardiac pressures. Different clinical, laboratory, and imaging utilities should be used to assess congestion and its dynamic changes (see Supplementary data online, Table S12). Hypoperfusion is not a synonym for hypotension,474,475 although patients with DHF and hypotension also experience inadequate perfusion. An objective marker, serum lactate, may help identify patients with peripheral hypoperfusion and monitor therapy.465 Signs and symptoms associated with congestion and hypoperfusion are reported in Table 12. Four categories of DHF can be recognized based on clinical presentation: decompensated left-sided HF, decompensated right-sided HF, acute pulmonary oedema (APO), and cardiogenic shock (CS). Pathophysiology, timing of onset, and speed of deterioration differ between the four categories, but possible overlaps exist.

7.3.1. Decompensated left-sided heart failure Decompensated left-sided HF, in its classical clinical presentation, is characterized by a gradual onset of signs and symptoms with accumulating congestion as the primary pathophysiological process.476 It may occur in patients across the spectrum of LVEF and, in advanced stages, can lead to RV dysfunction and

In a small unblinded RCT, cardiac contractility modulation marginally improved peak oxygen uptake and QoL in patients with advanced HFrEF and a QRS <130 ms.438 In a small pilot study, cardiac contractility modulation improved the Kansas City Cardiomyopathy Questionnaire (KCCQ) score by 18 points in patients with HFpEF.439 No clinical outcome studies have emerged. Similarly, baroreceptor activation therapy led to improvements in 6-min walk distance and QoL in an unblinded RCT, but long-term clinical outcome data were neutral.440,441 Current evidence for these CIEDs is insufficient to support guideline recommendations. Although promising, these findings require confirmation in large, well-designed trials.439

Page 43 · PDF

shock; DHF, decompensated heart failure; ECG, electrocardiogram; LUS, lung ultrasound; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide. aSee Supplementary data online, Table S11 for more details on admission investigations in DHF. bIn case of APO or CS, early treatment is recommended. cThe currently recommended, non-age-adjusted, natriuretic peptide ‘rule-out’ thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL. Combination with age-related ‘likely’ rule-in thresholds may reduce unnecessary exams: NT-proBNP >450 pg/mL (<50 years), NT-proBNP >900 pg/mL (50– 74 years), NT-proBNP >1800 pg/mL (>74 years). dIn case of DHF unlikely, look for other causes of symptoms.

decompensated right-sided heart failure. Thus, both pulmonary and peripheral congestion may be present. Hypoperfusion can occur.447,465,476 Treatment is mainly based on decongestion by means of diuretic therapy. Site of care can be outpatient clinic or hospital.

7.3.2. Decompensated right-sided heart failure Decompensated isolated right-sided HF is characterized by elevated RV and right atrial pressures, leading to systemic congestion and, in more advanced stages, hypoperfusion. It is often

associated with tricuspid regurgitation (TR) and can also impair LV filling and reduce systemic cardiac output through ventricular interdependence. Pulmonary embolism and acute MI involving the right ventricle are possible causes of decompensated right HF that need to be excluded during initial evaluation and treated. Fluid overload, elevated central venous pressures, and multiorgan dysfunction are the most frequent elements of the clinical picture of the disease. In the most severe cases, it can manifest as a refractory shock. The RV function and its effect on other organs (kidney, liver) usually determine the clinical

Figure 11 Diagnosing decompensated heart failure. APO, acute pulmonary oedema; BNP, B-type natriuretic peptide; CS, cardiogenic

Page 44 · PDF

Table 12 Signs, symptoms, and altered laboratory tests in congestion and hypoperfusion profiles

SCAI classification for cardiogenic shock

A patient who is not currently

experiencing signs or symptoms of CS but is at risk for development of CS.

Peripheral oedema Abdominal distension

STAGE B ‘Beginning/pre-shock’

A patient who has clinical evidence of hemodynamic instability (including

relative hypotension or tachycardia)

Dizziness Mental confusion

Pleural effusion Elevated serum

Elevated bilirubin, ALP, GGT

A patient that manifests with

‘Classic’ cardiogenic shock

hypoperfusion requiring intervention (inotrope, vasopressor, or mechanical support).

A patient that is similar to stage C but

deteriorating with failure to respond to A patient with refractory shock or cardiac arrest requiring multiple simultaneous acute interventions, including CPR.

CPR, cardiopulmonary resuscitation; CS, cardiogenic shock; MI, myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions.

trajectory, thus a close monitoring of kidney and hepatic function is needed. Onset can be gradual or rapid depending on causes, triggers, and precipitating factors. Optimal care requires a multifaceted approach, including diuretics, judicious fluid management, appropriate use of inotropes and vasopressors, and mechanical circulatory support (MCS) when indicated.

7.3.3. Acute pulmonary oedema Acute pulmonary oedema is a life-threatening condition that needs prompt, optimally targeted rescue therapy.477,478 Clinical criteria for the diagnosis of APO include signs and symptoms of respiratory distress [dyspnoea with orthopnoea, respiratory failure (hypoxaemia with or without hypercapnia), tachypnoea (>25 breaths/min), and increased work of breathing], caused by massive pulmonary congestion, which typically develops over a short period of time.477 The major objectives of the treatment are relieving pulmonary congestion, treating respiratory insufficiency, and ensuring peripheral perfusion. The mechanism of development of congestion is complex, with a predominant fluid redistribution that implies pulmonary congestion without total volume overload, primarily due to blood shift into the pulmonary circulation. Such patients usually do not need high doses of diuretics, but they may need vasodilators. The cause of decompensation should be investigated in every patient, and causal treatment, if possible, is imperative.

7.3.4. Cardiogenic shock Cardiogenic shock is defined as a state of critical end-organ hypoperfusion caused by primary cardiac dysfunction.479–481 The Shock Academic Research Consortium (SHARC) consensus defines CS as a cardiac disorder that results in both clinical

and biochemical evidence of sustained tissue hypoperfusion.482 Generally, CS is characterized by hypoperfusion and hypotension; however, no specific blood pressure cut-off is defined, as CS is a complex clinical condition, involving many parameters and nuances. Thus, any arbitrary blood pressure threshold will have inherent limitations. CS may also present as hypoperfusion with normotension, which has better prognosis than hypotensive CS.483,484 Importantly, septic and hypovolaemic shock also manifests with hypotension and end-organ hypoperfusion, and mixed forms of shock often exist simultaneously.480,485 Clinical features of hypoperfusion are reported in Table 12. Biochemical manifestation of inadequate tissue perfusion is best measured by arterial lactate, where a value of >2 mmol/L is required.479,480 Additional markers used in assessment of hypoperfusion are acute kidney injury and/or acute hepatic injury.480 The Society for Cardiovascular Angiography and Interventions introduced a staging scheme—SCAI classification—to address the severity of CS.479 Based on this, there are five categories of CS: (A) at risk, (B) pre-shock, (C) classic, (D) deteriorating, and (E) extremis (Table 13).

7.4. General management In-hospital management of DHF can be divided into three general phases (Figure 12). Importantly, each clinical category of DHF has different trajectories through these phases. For instance, CS patients usually remain in phase 1 for several days and may never reach phase 2.474 On the other hand, patients with uncomplicated decompensated left-sided or right-sided HF or APO can experience quick transition through all phases of treatment.

initial interventions. STAGE E ‘Extremis’

ALP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase.

Page 45 · PDF

                             

                            

          

                     ­   €                                                  

Figure 12 Phases and goals for in-hospital management of decompensated heart failure. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure. aSee Figure 14.

7.4.1. Phase 1 (initial management) The primary objectives in phase 1 are reported in Figure 12. In many cases, this phase starts in pre-hospital settings. Pre-hospital management should not delay the rapid transfer of the patient to the most appropriate medical setting, where further work-up is undertaken. Patients should be triaged based on their haemodynamic and clinical status to determine the appropriate level of care and monitoring requirements. For patient risk stratification, specific scores have been proposed, but they need further validation (see Supplementary data online, Section S4.2.1).486,487 In patients with suspicion of CS and with a potential indication for temporary MCS, consultation with the Shock Team is recommended (see Section 7.5.11).488 In these patients, as well as in those with other life-threatening conditions, the diagnostic

work-up and appropriate rescue pharmacological and nonpharmacological treatment should be initiated promptly and simultaneously (Figure 13). Identification and possible treatment of acute causes is crucial.118,119,489–491 Combination and timing of different treatments depend on clinical presentation (Figure 13). In patients already receiving FMT, continuation and/or rapid reintroduction as soon as possible is recommended. Discontinuation of FMT is not recommended unless there are clear signs of hypoperfusion or specific clinical indications. Monitoring during and after initial stabilization is mandatory (see Supplementary data online, Table S12).

7.4.2. Phase 2 (stabilization) The primary objective of this phase is to maintain and enhance the patient’s haemodynamic status and, once the patient is

Page 46 · PDF

tween different clinical phenotypes can exist. bConsultation with the Shock Team is recommended. cConsider in case of hypoxaemia. Consider when systolic blood pressure is >110 mmHg.

stabilized, to start/optimize long-term FMT to alter the course of the disease and improve patient outcomes. Decongestion is crucial and must be started and continued in phase 2 (Figure 13). Data from recent RCTs have demonstrated that initiating MRAs, SGLT2-Is, or ARNIs is feasible and safe in this phase of DHF.281,492,493 Much debate is ongoing on the optimal FMT initiation/optimization. It is clear that the traditional sequential approach is suboptimal and time-consuming. There is growing evidence that simultaneous implementation of FMT is more effective, safe, and associated with clinical benefit, thus this approach should be preferred. As no prospective RCT has been conducted comparing the different approaches to implementing FMT, no specific recommendation can be made regarding the number of drug classes to be introduced simultaneously or sequencing of the drugs. A more conservative approach may be reserved for specific (high-risk) groups of patients, such as patients with low eGFR, hypotension, and history of hyperkalaemia.

7.4.3. Phase 3 (pre-discharge and early post-discharge) This transition phase covers the last days of hospitalization and the first days/weeks after discharge.494 During this period, efforts should focus on reducing the risk of subsequent DHF/WHF

episodes, further optimizing FMT, and determining any indications for AMT and GDIT. The STRONG-HF trial demonstrated the safety and efficacy of an approach based on a rapid and intensive initiation and uptitration of FMT followed by close outpatient visits.311 This study has been criticized due to several limitations, including a highly selected population (based on NT-proBNP values and changes), the suboptimal medical treatment in the control arm and the lack of SGLT2-I use (lack of evidence and recommendations at the time when the study was conducted). Nevertheless, the trial showed that a strategy of fast uptitration after HFH is safe and feasible and therefore this approach is recommended. Safety indicators, including vital signs (blood pressure and heart rate) and laboratory tests (creatinine, potassium, and NT-proBNP) are helpful to guide uptitration.495 Residual congestion is associated with poor outcomes and a high risk of rehospitalization. Thus, pre-discharge assessment of residual congestion using clinical, laboratory, and imaging techniques is recommended (Figure 14).494 If not done earlier, the predischarge phase may also be used for iron supplementation in patients with iron deficiency (ID), based on the results of the AFFIRM-AHF trial (see Section 10.4).496 Finally, patients should be enrolled in disease management and rehabilitation programmes, educated, and guided in appropriate lifestyle adjustments.

Figure 13 Initial management of decompensated heart failure. HF, heart failure; MCS, mechanical circulatory support. aOverlap be-

Page 47 · PDF

   ˆ   ˆ€•

  ∆≥      ­€‚ ƒ„   ­ ‚ ƒ„

†     ‡ˆ‰

  Šƒ‹­€ ‡ ∆Šƒ‹Œ‚‰

 “­ €„„    ”Œ‚   “­ €„„    ”Œ‚

 ­‚  ‡ ’ ’    ‰

  Šƒ‹­€‚ Šƒ ­ ŠŽ Œ€„ † ­ ‘’„ƒ

  ­€‚  ‡  ’    ‰

Figure 14 Tools used for assessment of decongestion during the pre-discharge phase. All these tools are intended to be optional as no evidence from randomized controlled trials exists. BNP, B-type natriuretic peptide; CSI, congestion score index; EDT, E-wave deceleration time; IVC, inferior vena cava; LUS, lung ultrasound; LV, left ventricular; NP, natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TRV, tricuspid regurgitation velocity. aCongestion score = 0 denotes the absence of clinical congestion (absence of dyspnoea, orthopnoea, fatigue, rales, oedemas, jugular vein distension).497 Congestion score = 1–2 denotes mild congestion (slight or moderate dyspnoea, orthopnoea, fatigue, rales, oedemas, jugular vein distension).497 bThe CSI is a six-zone evaluation of a chest X-ray, with individual scores ranging from 0 to 3. A total score of 0 indicates all zones are clear (i.e. no congestion). cThe IVC is an optional tool to assess decongestion, although CAVA-ADHF showed no added benefit498.

Recommendations Careful evaluationc before discharge is recommended in patients hospitalized for DHF to exclude persistent signs of congestion. An intensive strategy of rapid initiation and uptitration of FMT before discharge and during frequent follow-up visits in the first 6 weeks following an HFH is recommended to reduce the risk of HF rehospitalization or death.311 DHF, decompensated heart failure; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization. a Class of recommendation. b Level of evidence. c Clinical evaluation, natriuretic peptide levels (Table 9), kidney function and electrolytes, imaging (see Figure 14).

Recommendation Table 8 — Recommendations for pre-discharge and early post-discharge follow-up of patients hospitalized for decompensated heart failure (see Evidence Tables 59–67)

Page 48 · PDF

7.5. Treatment 7.5.1. Oxygen therapy Oxygen therapy is recommended in patients with hypoxaemia [oxygen saturation (SpO2) <90% or partial pressure of oxygen (PaO2) <60 mmHg]. Studies, including RCTs, have demonstrated that indiscriminate oxygen administration in non-hypoxaemic patients may be harmful.499–501

Non-invasive ventilation is recommended in patients with APO or CS and respiratory failure to improve oxygenation and reduce the need for intubation as shown by multiple trials and meta analyses.502,503 However, the increase in intrathoracic pressure with non-invasive positive pressure ventilation decreases venous return and right and left ventricular preload. It may also decrease cardiac output and blood pressure and should therefore be used with caution in patients with reduced preload reserve and hypotension (i.e. decompensated right-sided HF). Endotracheal intubation is reserved for selected cases (see Recommendation Table 9).477

7.5.3. Diuretics (decongestion management) Intravenous loop diuretics remain the cornerstone of decongestion in DHF. In the DOSE-AHF trial, no difference in the primary efficacy outcome of patients’ symptom global assessment was shown with a high-dose regimen compared with a low-dose regimen of furosemide. There is no evidence indicating differential outcomes with i.v. bolus administration compared to continuous infusion or that one loop diuretic is superior to another.327,504 Patients naïve to diuretics usually respond well to 40 mg of i.v. furosemide or equivalent, whereas i.v. doses of two times the patient’s usual oral diuretic dose should be considered for patients who have been on loop diuretics as outpatients.505 Possible worsening kidney function should be evaluated in the context of diuretic response, because small and transient rises in serum creatinine during diuretic therapy are not associated with poor outcome if decongestion is achieved.506,507 Subsequent doses of loop diuretics during the initial days of hospitalization may be adjusted based on urinary sodium (uNa+) assessments, diuretic response, and the patient’s clinical status. A satisfactory diuretic response can be defined as a uNa+ content ≥70 mEq/L at 2 h or by a urine output ≥100 mL/h during the first 6 h (Figure 15). The PUSH-AHF trial showed that a strategy based on frequent clinical assessment, and uNa+-guided diuretic therapy led to higher natriuresis at 24 h vs standard of care.508 In the ENACT-HF open-label study, the uNa+-based approach also resulted in higher natriuresis and diuresis, as well as shorter hospital stay.509 No clinical trial has thus far showed benefit of uNa+-guided diuretic therapy on death or recurrent HFH. Intravenous diuretics should be continued until optimal decongestion is achieved; then, a switch to oral diuretics, if needed to maintain the volume status, is recommended. If there is an insufficient diuretic response, the loop diuretic i.v. dose can be doubled and/or a non-loop diuretic added. (Figure 15). Two recent RCTs examined the role of non-loop diuretics for enhanced decongestion in DHF. In the ADVOR trial, patients

were randomized to i.v. acetazolamide (500 mg) or placebo added to i.v. loop diuretics. Treatment with acetazolamide resulted in a greater incidence of successful decongestion, defined as the absence of signs of volume overload within 3 days.510 In the CLOROTIC trial, oral hydrochlorothiazide (dose adjusted for eGFR) was compared with placebo in patients receiving i.v. furosemide.511 The treatment with hydrochlorothiazide resulted in more pronounced weight loss at 72 h but did not impact patientreported dyspnoea. Treatment with hydrochlorothiazide was associated with greater 24 h diuresis but also more likely worsened kidney function and hypokalaemia, warranting caution. Importantly, the study was prematurely halted due to slow recruitment. Both ADVOR and CLOROTIC did not show benefit of non-loop diuretics on hard endpoints. The pharmacotherapy of different diuretics and a practical guidance for their use in DHF is reported in Supplementary data online, Table S13. In patients with DHF, fluid intake should be less than urine output and fluid restriction may be appropriate in patients with hyponatraemia, based on individual assessment. Similarly, sodium intake should remain less than natriuresis. Implementing SGLT2-I and neurohormonal blockade, including MRA, can contribute to more effective and sustainable decongestion.512–514 Thus, it is imperative to consider early implementation and optimization of FMT in parallel to decongestion (Figure 15).

7.5.4. Decongestion management in the ambulatory setting In ambulatory patients with chronic HF showing signs of worsening, both i.v. diuretic administration and intensification of oral diuretic therapy can be considered. A practical guide for the outpatient management of WHF has been published, covering both ambulatory i.v. diuretics administered in a day-hospital setting and ‘hospital-at-home’ care models, including telehealth-enabled approaches.515–517 Diuretic sessions usually consist of a 3–6 h i.v. diuretic infusion with dosing based on the patient’s existing oral diuretic regimen. Close monitoring of kidney function, electrolyte levels, and treatment response, including measurements of urine output, uNa+, signs of clinical decongestion, biomarkers, and/or ultrasound findings, is essential.444,515,518 The new formulations of diuretics (e.g. subcutaneous) might be particularly useful for home treatment.519–521 Intensification of oral diuretic therapy may include: (i) initiating a loop diuretic in previously untreated individuals; (ii) increasing the total daily dose of a loop diuretic; or (iii) temporarily adding a diuretic with a different mechanism of action. Thiazide-like diuretics—particularly oral metolazone (2.5–5 mg)—can be used in patients with advanced HF who exhibit diuretic resistance, as part of a sequential nephron blockade approach, or in those with an eGFR <30 mL/min/1.73 m2. This strategy requires careful monitoring of eGFR and electrolytes. Patients with WHF that progresses to advanced HF are a key population for either outpatient i.v. diuretic treatment, whether in a day hospital or ‘hospital-at-home’ setting, or oral thiazidelike diuretics. Indeed, these patients often experience frequent hospitalizations and spend a substantial amount of time in hospital (‘frequent flyers’). Such patients require prompt evaluation for advanced HF treatments (see Section 8).

7.5.2. Ventilation support

Page 49 · PDF

Start i.v. loop diuretic (40 mg furosemide in diuretic naive or double daily oral dose in chronic users)a

Repeat the diuretic regime every 12 h until complete decongestionb

Double the dose of loop diuretic OR Consider adding i.v. acetazolamide or eGFR based hydrochlorothiazidec (in case of chronic loop diuretic use)

Spot uNa+ at 2–6 h ≥70 mmol/L OR Urine output at 6h ≥100 mL/h

Progressive escalation of loop diuretics up to the maximum i.v. dosed AND Consider adding other non-loop diuretics

Consider ultrafiltration in case of unsuccessful decongestion despite maximal diuretic therapy

FMT initiation/uptitration Check frequently for hypotension/hypoperfusion. Check serum creatinine and electrolytese at least every 24 h

Figure 15 Management of decongestion. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FMT, foundational

medical therapy; i.v., intravenous; K+, potassium; MRA, mineralocorticoid receptor antagonist; uNa+, urinary sodium. aHigher initial i.v. dose in case of CKD. bAfter 24 h of treatment, total diuresis should be taken into consideration. If diuresis remains <3 l and congestion persists, further diuretic escalation should be considered during the second day of treatment. cAcetazolamide (500 mg i.v. once daily) or hydrochlorothiazide (if eGFR >50 mL/min/1.73 m2: 25 mg daily; eGFR 20–50 mL/min/1.73 m2: 50 mg daily; and eGFR <20 mL/min/ 1.73 m2: 100 mg daily). Acetazolamide might be preferable in more advanced CKD. dThe highest daily dose for i.v. loop diuretics is generally considered furosemide 600 mg, although up to 1000 mg may be considered in patients with severely impaired kidney function. e Consider MRA and K+ supplements in case of hypokalaemia.

Spot uNa+ at 2 h ≥70 mmol/L OR Urine output at 6h ≥100 mL/h

Page 50 · PDF

50 7.5.5. Sodium–glucose co-transporter 2 inhibitors

use of norepinephrine as first choice, compared with dopamine or epinephrine. Dopamine vs norepinephrine was associated with significantly higher rate of arrhythmic events in an RCT including patients with unspecified shock.538 In the CS subgroup, a mortality benefit was observed with norepinephrine, although without a significant P-value for interaction. Comparing epinephrine and norepinephrine showed similar effects on cardiac index in a small trial of infarct-related CS.539 However, this trial was stopped prematurely due to a higher incidence of refractory shock with epinephrine. Vasopressin has not been studied in CS so far. The target mean blood pressure is not well defined in CS. For more details, see Supplementary data online, Table S16.

7.5.10. Opiates 7.5.6. Ultrafiltration Given the available data, the role of ultrafiltration in managing DHF remains uncertain, but it may be considered in selected patients who are responding insufficiently to diuretic escalation.527,528

7.5.7. Vasodilators Intravenous vasodilators (i.v. nitroglycerine or nitroprusside) may be effective in patients with DHF, particularly in those with predominant vasoconstriction and volume redistribution. For example, in APO, where increased cardiac filling pressures and elevated systemic blood pressures occur in the absence of, or with minimal, systemic fluid accumulation, vasodilators can reduce pulmonary congestion (Supplementary data online, Section S4.3 and Table S14).529 Importantly, close monitoring of blood pressure is recommended during drug administration, as hypotension related to vasodilatation may be harmful.529,530 None of the large-scale RCTs have shown a clear clinical benefit of vasodilatation on hard endpoints.531–533 A meta-analysis of available RCTs has demonstrated that using vasodilators was associated with a lower risk of tracheal intubation in DHF with no effect on death or length of hospital stay.534

7.5.8. Inotropes/inodilators Inotropic agents may be considered in patients with DHF, systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion. Due to risks of arrhythmias and myocardial ischaemia, their use is not routinely recommended in patients with DHF and should be cautious.535 A Cochrane analysis found insufficient evidence to establish mortality benefits of any inotrope in patients with CS or low cardiac output.536 An RCT found no difference between milrinone and dobutamine.537 For levosimendan, no relevant RCTs in CS are available. Based on the mode of action, levosimendan or phosphodiesterase-III inhibitors may be preferred over dobutamine for patients on beta-blockers. For more details on the specific inotropic agents, see Supplementary data online, Tables S15 and S16.

7.5.9. Vasopressors Vasopressors may be considered in patients with hypotension and DHF. Some studies, although with limitations, support the

Routine use of opiates is not recommended in patients with DHF; Their use should be limited to carefully selected patients with severe anxiety or distress refractory to other treatments and must be approached with caution due to the risk of respiratory failure.

Recommendation Table 9 — Recommendations for the immediate and intermediate treatment of decompensated heart failure (see Evidence Tables 59–67) Recommendations

Oxygen and ventilatory support Oxygen is recommended in patients with SpO2 <90% or PaO2 <60 mmHg to correct hypoxaemia. Intubation is recommended in patients with DHF and persistent and progressive respiratory failure despite oxygen administration or non-invasive ventilation to correct hypoxaemiac. Non-invasive positive pressure ventilation should be considered in patients with respiratory distress (respiratory rate >25 breaths/min, SpO2 <90%) and started as soon as possible in order to decrease respiratory distress and reduce the risk of endotracheal intubation.540 Diuretics Intravenous loop diuretics are recommended for all patients with DHF admitted with fluid overload to improve symptomsd. The addition of short-term intravenous acetazolamide or oral hydrochlorothiazide should be considered in patients with fluid overload previously treated with loop diuretics, to reduce congestion.510,511 Urinary Na+-guided diuretic therapy may be considered during the first days of treatment of patients with DHF to improve natriuresis and diuresis.508 Continued

Several trials and meta-analyses have confirmed the safety and clinical benefit of in-hospital initiation of an SGLT2-I.492,522–525 The EMPULSE trial demonstrated that in-hospital initiation of 10 mg empagliflozin resulted in significantly higher chances of clinical benefit, at 90 days.492 In the SOLOIST-WHF trial, initiation of sotagliflozin in hospital or within 3 days of discharge was safe and effective in patients with HF and diabetes.326 Initiation of SGLT2-Is in HF has been shown to be associated with lower diuretic demand and facilitated decongestion even though the long-term ‘diuretic effect’ of SGLT2-Is is unknown.514,522–524,526 Thus, early initiation of SGLT2-Is in DHF is recommended both as part of FMT (i.e. prognostic implications) and as a tool to enable optimal decongestion (Figure 15).

Page 51 · PDF

suggests that temporary MCS are beneficial in highly selected patients with ST-elevation MI complicated by CS who do not have hypoxic brain injury, although rates of severe complications remain high.546

SGLT2-I In-hospital initiation of SGLT2-I is recommended in patients with DHF after initial stabilization to improve QoL and congestion

symptoms and reduce the risk of HFH.492,522,525,541

7.5.11.1. Microaxial flow pumps

Vasodilators initial therapy in patients with DHF and systolic blood pressure >110 mmHg to improve

symptoms and reduce congestion.534 Inotropic agents Inotropic agents may be considered in patients with systolic blood pressure <90 mmHg and evidence of hypoperfusion who do not respond to standard treatment, including fluid challenge, to improve perfusion. Vasopressors Vasopressors, preferably norepinephrine, may be considered in patients with cardiogenic shock to increase blood pressure and vital organ Opiates Routine use of opiates is not recommended in patients with DHF unless severe/intractable pain or anxiety, due to risk of harm.542

DHF, decompensated heart failure; HFH, heart failure hospitalization; NIV, non-invasive ventilation; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen; QoL, quality of life; SGLT2-I, sodium–glucose co-transporter 2 inhibitor; SpO2, oxygen saturation. a Class of recommendation. b Level of evidence. c Criteria for endotracheal intubation in DHF: cardiac or respiratory arrest, progressive worsening of altered mental status, progressive worsening of respiratory failure with hypoxaemia (PaO2 <60 mmHg, PaCO2 >50 mmHg and pH <7.35) despite NIV or intolerance to NIV, persistent haemodynamic instability, need for airway protection.477 d This recommendation is considered by the Task Force to have level of evidence A due to clear clinical benefit. Treatment of DHF with loop diuretics has been widely accepted as effective and therefore no adequately powered randomized clinical trial has ever been conducted or is likely to be conducted for ethical reasons.

7.5.11. Temporary mechanical circulatory support Temporary MCS should be considered as an option for stabilizing haemodynamics and enhancing end-organ perfusion in highly selected patients.434,474,543,544 Different percutaneous devices operate through distinct mechanisms, delivering diverse haemodynamic support levels, each associated with specific potential benefits but also possible complications. In addition to single use, multiple combinations are feasible, addressing specific needs for LV unloading or combined left and right ventricular support. Decisions on the modality and type of temporary MCS should be guided by a multidisciplinary Shock Team including a cardiologist specialized in HF, a cardiothoracic surgeon, an interventional cardiologist, and an intensive care specialist, working at an experienced advanced HF centre (i.e. highvolume for temporary MCS).488,545 A recent meta-analysis

7.5.11.2. Venoarterial extracorporeal life support Extracorporeal life support (ECLS) can deliver support of up to 6 l/min and provide full respiratory and circulatory support. In the ECLS-SHOCK trial involving patients with severe infarct-related CS, early routine ECLS use showed no significant difference in 30-day all-cause death (relative risk 0.98; 95% CI 0.80–1.19).552 These data are in line with an individual patient data meta-analysis of ECLS RCTs in patients with infarct-related CS in which no mortality benefit was observed but more complications with ECLS were seen.553 Importantly, ECLS may harm the heart itself owing to the afterload increase by generation of retrograde blood flow. Active unloading with microaxial flow pumps or intra-aortic balloon pump (IABP) aims to mitigate these adverse effects. A recent RCT comparing routine LV unloading by a transseptal left atrial cannula vs ECLS alone showed no effect on death.554 RCTs investigating the efficacy of ECLS in non-ischaemic CS have yet to be performed.

7.5.11.3. Intra-aortic balloon pump Routine use of IABP is not recommended in unselected patients with CS. In the IABP shock trial, 40 patients with post-MI CS were randomised to IABP treatment or standard of care. Treatment with IABP did not significantly augment cardiac output or any other haemodynamic variable as compared to control.555 In a large-scale RCT in infarct-related CS, routine use of IABP did not show a survival benefit compared with medical therapy at 30-day and longer follow-up.556–558 Also, in advanced HF CS, IABP had no survival benefit as compared to standard of care.559,560 The decision to use an IABP should therefore be highly individualized, based on patient-specific factors and the availability of alternative therapies.559,561–563

Intravenous vasodilators may be considered as

Microaxial percutaneous flow pumps provide support of up to 4 l/min. Newer devices with 5.5 l/min requiring surgical insertion offer complete LV support. Until recently, the percutaneous device had been investigated in a few RCTs on infarct-related CS and in large-scale propensity-matched studies encompassing more than 100 000 patients and consistently showed no survival benefit with higher complication rates such as major bleeding and limb ischaemia.547,548 In the DanGer Shock trial, including 360 highly selected patients with ST-elevation MI and CS, treatment with microaxial flow pump vs standard of care was associated with lower 180-day death (HR 0.74; 95% CI 0.55–0.99; P = .04), which persisted up to 10-year follow-up.549,550 This trial also showed an increased incidence of bleeding and limb ischaemia compared with controls. Despite the mortality benefit observed in this trial, multiple open questions remain.548,551 Utilization of microaxial flow pumps should be considered in highly selected patients with CS caused by ST-elevation MI, who do not have risk of hypoxic brain injury. Routine use of microaxial flow pumps in CS is not recommended. RCTs on the efficacy of microaxial flow pumps in non-infarct-related CS have yet to be conducted.546

Page 52 · PDF

Recommendation Table 10 — Recommendations for the use of temporary mechanical circulatory support in patients with cardiogenic shock (see Evidence Tables 68 and 69)

A multidisciplinary Shock Team is recommended in potential candidates for temporary MCS to guide the device selection (modality and type)

based on patient and HF characteristics.564,565 Cardiogenic shock caused by acute MI Temporary MCS with a microaxial flow pump should be considered in selected patients with cardiogenic shock caused by ST-elevation MI with left ventricular systolic dysfunction and no

risk of hypoxic brain injuryc in order to reduce the risk of death.546,549,550 Temporary MCS is not recommended in unselected patients with cardiogenic shock caused by acute MI, due to risk of

All the following criteria must be present despite FMT, AMT, and GDIT: 1. Severe and persistent symptoms of HF (NYHA class III or IV). III

2. Severe cardiac dysfunction defined by at least one of the

• LVEF ≤30% • Isolated RV failure (e.g. ARVC)

IABP is not recommended in unselected patients with cardiogenic shock, due to the lack of effect.557,560

• Non-operable severe valve abnormalities • Non-operable severe congenital abnormalities • Persistently high (or increasing) BNP or NT-proBNP values and

MI-related mechanical complications Temporary MCSd should be considered in patients with mechanical complications related

Criteria for definition of advanced heart failure

severe LV diastolic dysfunction or structural abnormalities (i.e. IIa

HFpEF,a hypertrophic or restrictive cardiomyopathies).

3. Episodes of pulmonary or systemic congestion requiring high-dose

Advanced HF cardiogenic shock

i.v. diuretics (or diuretic combinations) or malignant arrhythmias causing ≥2 unplanned visits or hospitalizations in the last 12 months,

Temporary MCS should be considered in selected patients with HF-related haemodynamic instability as a BTR, BTD, BTB,

BTC, or BTT. BTB, bridge to bridge; BTC, bridge to candidacy; BTD, bridge to decision; BTR, bridge to recovery; BTT, bridge to transplantation; HF, heart failure; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; MI, myocardial infarction; VA-ECLS, venoarterial extracorporeal life support. a Class of recommendation. b Level of evidence. c No risk of hypoxic brain injury was defined as: (i) no out-of-hospital cardiac arrest with persistent Glasgow coma scale <8 after return of spontaneous circulation549; and (ii) no resuscitation or resuscitation lasting <10 min.546 d The choice of passive IABP or active percutaneous MCS should be based on the severity of cardiogenic shock as assessed by the Shock Team. e In case of large ventricular septal defect, temporary MCS should be used with caution due to the potential increase of left-to-right interventricular shunt (VA-ECLS) or shunt inversion (microaxial flow pump). In case of ventricular free-wall rupture, temporary MCS should be avoided; however, VA-ECLS can be considered to allow emergent cardiac surgery in patients presenting with profound cardiogenic shock and/or cardiac arrest if no sign of irreversible brain injury is present.

7.5.12. Thromboembolism prophylaxis Although patients with DHF are recognized as being at increased thromboembolic risk, no RCT has compared anticoagulation vs placebo in a DHF population, thus no definitive recommendation can be made.566–570 However, in case of immobilization or other risk factors, thromboembolic prophylaxis is generally indicated.

to MI as a bridge to definitive treatment.

or ≥1 episode of low output requiring inotropes or vasoactive drugs. 4. Severe impairment of exercise capacity with inability to exercise, or low 6-min walk test distance (<300 m), or pVO2 <12–14 mL/kg/ min,b or <50% predicted value, estimated to be of cardiac origin. AMT, additional medical therapy; ARVC, arrhythmogenic right ventricular cardiomyopathy; BNP, B-type natriuretic peptide; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; i.v., intravenous; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; pVO2, peak oxygen consumption; RV, right ventricular. a See Table 10. b The cut-off 12 mL/kg/min refers to patients on beta-blocker.

A severely reduced LVEF is common but not required for a diagnosis of advanced HF, as it may develop in patients with HFpEF or other structural abnormalities. Early risk stratification and timely referral to an advanced HF centre are crucial to improve outcomes (Figure 16).574,575 Systematic assessment for advanced HF using the ‘Rule of three’ or ‘I NEED HELP’ criteria is essential for timely referral to an advanced HF centre576–578 (Figure 16 and Table 15). Cardiopulmonary exercise testing and right heart catheterization (RHC) are key tools for risk stratification and eligibility assessment.579–582 Women and sociocultural minority groups are less likely to receive MCS and heart transplantation for reasons not explained by medical factors or social determinants of health and deserve extra attention for timely referral and patient communication.583–585

Many patients with HF progress into a phase of advanced HF (stage D), characterized by persistent severe symptoms and objective measures of cardiogenic impairment despite optimal therapy. In the Framingham population, 5.1%–7.7% of patients with HF had advanced HF.571 Prognosis in medically treated patients with advanced HF remains poor with 1-year mortality >40%.572,573 Criteria for definition are reported in Table 14.572

8.1. Epidemiology, definition, prognosis, and referral